Innate immune responses to AAV vectors

Gene replacement therapy by in vivo delivery of adeno-associated virus (AAV) is attractive as a potential treatment for a variety of genetic disorders. However, while AAV has been used successfully in many models, other experiments in clinical trials and in animal models have been hampered by undesi...

Full description

Bibliographic Details
Main Authors: Geoffrey L Rogers, Ashley T Martino, George V Aslanidi, Giridhara R Jayandharan, Arun eSrivastava, Roland W. Herzog
Format: Article
Language:English
Published: Frontiers Media S.A. 2011-09-01
Series:Frontiers in Microbiology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fmicb.2011.00194/full
_version_ 1818108485012815872
author Geoffrey L Rogers
Ashley T Martino
George V Aslanidi
Giridhara R Jayandharan
Arun eSrivastava
Roland W. Herzog
author_facet Geoffrey L Rogers
Ashley T Martino
George V Aslanidi
Giridhara R Jayandharan
Arun eSrivastava
Roland W. Herzog
author_sort Geoffrey L Rogers
collection DOAJ
description Gene replacement therapy by in vivo delivery of adeno-associated virus (AAV) is attractive as a potential treatment for a variety of genetic disorders. However, while AAV has been used successfully in many models, other experiments in clinical trials and in animal models have been hampered by undesired responses from the immune system. Recent studies of AAV immunology have focused on the elimination of transgene-expressing cells by the adaptive immune system, yet the innate immune system also has a critical role, both in the initial response to the vector and in prompting a deleterious adaptive immune response. Responses to AAV vectors are primarily mediated by the TLR9 MyD88 pathway, which induces the production of proinflammatory cytokines by activating the NF κB pathways and inducing type I IFN production; self-complementary AAV vectors enhance these inflammatory processes. Additionally, the alternative NF κB pathway influences transgene expression in cells transduced by AAV. This review highlights these recent discoveries regarding innate immune responses to AAV and discusses strategies to ablate these potentially detrimental signaling pathways.
first_indexed 2024-12-11T02:16:06Z
format Article
id doaj.art-adfbdf359ff546ca991f775753ec380a
institution Directory Open Access Journal
issn 1664-302X
language English
last_indexed 2024-12-11T02:16:06Z
publishDate 2011-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Microbiology
spelling doaj.art-adfbdf359ff546ca991f775753ec380a2022-12-22T01:24:11ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2011-09-01210.3389/fmicb.2011.0019412155Innate immune responses to AAV vectorsGeoffrey L Rogers0Ashley T Martino1George V Aslanidi2Giridhara R Jayandharan3Arun eSrivastava4Roland W. Herzog5University of FloridaUniversity of FloridaUniversity of FloridaChristian Medical CollegeUniversity of FloridaUniversity of FloridaGene replacement therapy by in vivo delivery of adeno-associated virus (AAV) is attractive as a potential treatment for a variety of genetic disorders. However, while AAV has been used successfully in many models, other experiments in clinical trials and in animal models have been hampered by undesired responses from the immune system. Recent studies of AAV immunology have focused on the elimination of transgene-expressing cells by the adaptive immune system, yet the innate immune system also has a critical role, both in the initial response to the vector and in prompting a deleterious adaptive immune response. Responses to AAV vectors are primarily mediated by the TLR9 MyD88 pathway, which induces the production of proinflammatory cytokines by activating the NF κB pathways and inducing type I IFN production; self-complementary AAV vectors enhance these inflammatory processes. Additionally, the alternative NF κB pathway influences transgene expression in cells transduced by AAV. This review highlights these recent discoveries regarding innate immune responses to AAV and discusses strategies to ablate these potentially detrimental signaling pathways.http://journal.frontiersin.org/Journal/10.3389/fmicb.2011.00194/fullGene Therapyinnate immunityAAV vectors
spellingShingle Geoffrey L Rogers
Ashley T Martino
George V Aslanidi
Giridhara R Jayandharan
Arun eSrivastava
Roland W. Herzog
Innate immune responses to AAV vectors
Frontiers in Microbiology
Gene Therapy
innate immunity
AAV vectors
title Innate immune responses to AAV vectors
title_full Innate immune responses to AAV vectors
title_fullStr Innate immune responses to AAV vectors
title_full_unstemmed Innate immune responses to AAV vectors
title_short Innate immune responses to AAV vectors
title_sort innate immune responses to aav vectors
topic Gene Therapy
innate immunity
AAV vectors
url http://journal.frontiersin.org/Journal/10.3389/fmicb.2011.00194/full
work_keys_str_mv AT geoffreylrogers innateimmuneresponsestoaavvectors
AT ashleytmartino innateimmuneresponsestoaavvectors
AT georgevaslanidi innateimmuneresponsestoaavvectors
AT giridhararjayandharan innateimmuneresponsestoaavvectors
AT arunesrivastava innateimmuneresponsestoaavvectors
AT rolandwherzog innateimmuneresponsestoaavvectors